Psoriasis drug tested for hidden heart benefits
NCT ID NCT04271540
Summary
This study tested whether tildrakizumab, an FDA-approved drug for moderate-to-severe psoriasis, could improve how well the heart's tiny blood vessels work. Researchers enrolled 36 adults with psoriasis who also had risk factors for heart disease. They used heart imaging scans to measure blood flow before and after 6 months of treatment to see if reducing skin inflammation also helps the heart.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.